Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$73.43 USD

73.43
684,127

+0.80 (1.10%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $73.40 -0.03 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Globus Medical (GMED) Stock Fell on Preliminary Q1 Sales Results

Globus Medical's (GMED) Q1 preliminary sales results reflect an increase in procedural volumes along with growth in Enabling Technologies business.

Riya Anand headshot

Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

Globus Medical (GMED) Tops Q4 Earnings and Revenue Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 2.08% and 2.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Q4 Earnings and Revenues Surpass Estimates

Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Globus Medical (GMED) Q4 Earnings Expected to Decline

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Lags Q4 Earnings and Revenue Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -7.27% and 1.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Encompass Health (EHC) to Spin Off Home Health & Hospice Unit

Encompass Health (EHC) expects the Enhabit Home Health & Hospice spinoff to be completed in first-half 2022.

Ensign Group (ENSG) Up 7.4% in 3 Months: More Growth Ahead?

Ensign Group (ENSG) is likely to keep growing on the back of Skilled services and impressive financial strength.

Molina Healthcare (MOH) Up 14.4% in 6 Months: Growth Ahead?

Molina Healthcare (MOH) is likely to keep growing on the back of increasing membership and higher premium revenues.

Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits

Select Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations.

Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day

Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day

Urmimala Biswas headshot

Omicron Hits Elective MedTechs, 3 Subsectors Likely to Thrive

Here we discuss three major subsectors of MedTech and three constituent stocks, OPCH, GMED and OMCL for which the change in the scenario has opened up enormous growth prospects.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical

NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.

Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag

Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.

Globus Medical (GMED) Q3 Earnings Beat Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 11.11% and -0.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) Progresses With ExcelsiusGPS in DBS

According to Globus Medica (GMED), the clinical superiority of ExcelsiusGPS continues to be recognized by surgeons.

Here's Why You Should Retain Globus Medical (GMED) for Now

Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.

Globus Medical (GMED) Up 4.9% Since Last Earnings Report: Can It Continue?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Globus Medical (GMED) Gets FDA Nod for Excelsius3D

The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.

Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up

Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.